Evidence map›Paper›PMID 29374786›Full record

ArticleJournal of cancer research and clinical oncology2018

Metal-free salan-type compound induces apoptosis and overcomes multidrug resistance in leukemic and lymphoma cells in vitro.

Maxim Dragoun, Thomas Günther, Corazon Frias, Albrecht Berkessel, Aram Prokop

Open access · greenAbstract read
In one paragraph

Article in Journal of cancer research and clinical oncology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.6field-weighted citation impact, top 30% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 11 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 2 institutions in 1 country.

Maxim DragounDepartment of Pediatric Hematology/Oncology, Children's Hospital Cologne, Amsterdamer Straße 59, 50735, Cologne, Germany. maximdragoun@gmail.com.ORCID http://orcid.org/0000-0003-1308-0196
Thomas GüntherDepartment of Chemistry, Organic Chemistry, University of Cologne, Greinstraße 4, 50939, Cologne, Germany.
Corazon FriasDepartment of Pediatric Hematology/Oncology, Children's Hospital Cologne, Amsterdamer Straße 59, 50735, Cologne, Germany.
Albrecht BerkesselDepartment of Chemistry, Organic Chemistry, University of Cologne, Greinstraße 4, 50939, Cologne, Germany.
Aram ProkopDepartment of Pediatric Hematology/Oncology, Children's Hospital Cologne, Amsterdamer Straße 59, 50735, Cologne, Germany.
University Hospital Cologne · DEUniversity of Cologne · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeWe report on our preclinical findings of a simple salicylic diamine compound (THG 1213) which has yielded exceptional results as a potential chemotherapeutic drug. THG 1213 is an easy to synthesize chiral and metal-free salan compound.

methodsTHG 1213 was tested on several leukemia, lymphoma and solid tumor cell lines in vitro. The effects have been studied by LDH release essay, FACS flow cytometry, photometric cell count, immunoblotting, and NMR spectroscopy.

resultsTHG 1213 selectively inhibits proliferation and induces apoptosis in leukemia, lymphoma and solid tumor cell lines. Necrosis or effects on healthy leucocytes could not be detected. Apoptosis is induced via the intrinsic and extrinsic pathways. The salan THG 1213 overcomes multidrug resistance in tumor cells and acts synergistically with vincristine and daunorubicin.

conclusionsTHG 1213 displays remarkable antitumor properties. In particular, the lack of metallic components of THG 1213 could prove to be beneficial in future clinical trials, as metal-containing drugs are known to show severe side effects.

Indexed as

Antineoplastic Combined Chemotherapy ProtocolsApoptosisCell Line, TumorDaunorubicinDrug Resistance, MultipleDrug Resistance, NeoplasmDrug SynergismHumansLeukemiaLymphomaNeoplasmsPhenylenediaminesSalicylatesVincristineDaunorubicinPhenylenediaminesSalicylatesVincristineApoptosisCancerLeukemiaMultidrug resistanceSalan

Identifiers

PMID29374786
PMCPMC11813336
OpenAlexW2789995502

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.